

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226629 A1

(51) International Patent Classification:

A61K 31/5375 (2006.01) *A61K 31/517* (2006.01)
C07D 239/72 (2006.01) *C07H 19/22* (2006.01)
C07D 265/28 (2006.01) *A61K 31/47* (2006.01)
C07D 243/34 (2006.01)

(21) International Application Number:

PCT/US2021/070507

(22) International Filing Date:

04 May 2021 (04.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/019,772 04 May 2020 (04.05.2020) US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **VIGIL NEUROSCIENCE, INC.** [US/US]; 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **CZABANIUK, Lara, C.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **HOPPER, Timothy**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **HOUZE, Jonathan, B.**; c/o Vigil Neurosciences, Inc., 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139 (US). **PANTELEEV, Jane**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **RESCOURIO, Gwenaella**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **SANTORA, Vincent**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WANG, Haoxuan**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WHITE, Ryan D.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WONG, Alice, R.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WU, Yongwei**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **BOS, Maxence**; c/o NuChem Therapeutics Inc., 2350 Cohen Street, Suite 201, Saint-Laurent, Québec H4R 2N6 (CA). **MANCUSO, John**; c/o NuChem Therapeutics Inc., 2350 Cohen Street, Suite 201, Saint-

Laurent, Québec H4R 2N6 (CA). **FRANZONI, Ivan**; c/o NuChem Therapeutics Inc., 2350 Cohen Street, Suite 201, Saint-Laurent, Québec H4R 2N6 (CA).

(74) Agent: **REID, Andrea, L., C.** et al.; Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, 02110 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE



(57) Abstract: The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).